the aid library

LIST OPTIONS

Filter

7999

Sort by:

Direction:

Download (358)

View PDF (823)

Joint Review of HIV, TB and PMTCT Programmes in South Africa. Main Report

Ministry of Health, South Africa Joint HIV, TB and PMTCT Review Steering committee (2014) C1

Download (816)

View PDF (2130)

PMTCT in Humanitarian Settings. Part II: Implementation Guide

Becher, H.; et al. Interagency Task Team HIV in Humanitarian Emergencies (2015)

front cover © Jonathan Hyams/Save the Children

Download (620)

View PDF (917)

Identificación y tratamiento del síndrome de Guillain-Barré en el contexto del brote de virus de Zika

Organización Mundial de la Salud (2016) C_WHO

El objetivo del presente documento consiste en ofrecer orientaciones provisionales sobre la definición de los casos de SGB y las estrategias para tratar el síndrome en el contexto del brote de virus de Zika y de su posible relación con el SGB. Asimismo, pretende servir como base para la elab... more

Download (420)

View PDF (1117)

National Training Package on Paediatric HIV and AIDS Care and Treatment. Participants Handbook. Module 5: Adherence to Medication for Children and Adolescents

Ministry of Health and Social Welfare, National AIDS Control Programme, Tanzania (2015) C1

Download (871)

View PDF (1434)

National Training Package on Paediatric HIV and AIDS Care and Treatment. Participants Handbook. Module 7: Psychosocial Support Issues in Pediatric HIV

Ministry of Health and Social Welfare, National AIDS Control Programme, Tanzania (2015) C1

Download (476)

View PDF (1115)

National Training Package on Paediatric HIV and AIDS Care and Treatment. Participants Handbook. Module 9: HIV and Primary Health Care

Ministry of Health and Social Welfare, National AIDS Control Programme, Tanzania (2015) C1

Download (866)

View PDF (1276)

National Training Package on Paediatric HIV and AIDS Care and Treatment. Participants Handbook: Module 2 Diagnosis and Staging of HIV Disease

Ministry of Health and Social Welfare, National AIDS Control Programme, Tanzania (2015) C1

Download (116)

View PDF (143)

Cotonou declaration on buruli ulcer

World Health Organization WHO (2009) CC

Cotonou Declaration oBuruli Ulcer Cotonou, Benin, 30 March 2009 Neglected tropical diseases kill, weaken or incapacitate millions of people every year, causing permanent physical suffering, social stigmatization and reduced productive capacity. Buruli ulcer, one such disease, causes immense suffer... more

Download (115)

View PDF (172)

Progress towards elimination of lymphatic filariasis in the Eastern Mediterranean Region

R. M. R. Ramzy; Al Kubati, A. S. International Health (2021) C1

Lymphatic filariasis (LF), a neglected tropical disease, is targeted for global elimination as a public health problem. This article reviews the history of LF control and elimination activities in the countries of the World Health Organization's (WHO) Eastern Mediterranean Region (EMR) over the last... more

Download (120)

View PDF (166)

Progress in the elimination of lymphatic filariasis in the Western Pacific Region: successes and challenges

A. Yajima; Ichimori, K. International Health (2020) C1

The Western Pacific Region is the largest and most diverse region in the world, made up of 37 countries and territories in the Pacific, Oceania and parts of Asia, with a population of more than 1.9 billion people stretching over an area from China and Mongolia in the north to New Zealand in the sout... more

Download (106)

View PDF (165)

Dengue epidemiology

Jing, Q.; Wang, M. Global Health Journal (2019) CC

Dengue is the fastest spreading, mosquito-borne viral infectious disease worldwide, with remarkable morbidity and mortality. In the past decades, profound contributions have been made towards understanding its epidemiology, including disease burden and distributions, risk factors, and control and pr... more

Download (85)

View PDF (716)

Fexinidazole for Human African Trypanosomiasis, the Fruit of a Successful Public-Private Partnership.

Bernhard, S.; Kaiser, M.; Burri, C.; Mäser, P. Diseases (2022) CC

After 100 years of chemotherapy with impractical and toxic drugs, an oral cure for human African trypanosomiasis (HAT) is available: Fexinidazole. In this case, we review the history of drug discovery for HAT with special emphasis on the discovery, pre-clinical development, and operational challenge... more

Download (64)

View PDF (356)

Leptospiral Infection, Pathogenesis and Its Diagnosis

Samrot, A.; Sean, T.; Bhavya, K.; et al. (2021) CC

Leptospirosis is a perplexing conundrum for many. In the existing literature, the pathophysiological mechanisms pertaining to leptospirosis is still not understood in full. Considered as a neglected tropical zoonotic disease, leptospirosis is culminating as a serious problem worldwide, seemingly exi... more

Download (89)

View PDF (135)

African regional progress and status of the programme to eliminate lymphatic filariasis: 2000–2020

Deribe K., Bakajikaa D. K., Zourea H. MG. et al The royal society of tropical medicine and hygiene (2021) C2

To eliminate lymphatic filariasis (LF) by 2020, the World Health Organization (WHO) has launched a campaign against the disease. Since the launch in 2000, significant progress has been made to achieve this ambitious goal. In this article we review the progress and status of the LF programme in Afric... more

Download (70)

View PDF (365)

Challenges and opportunities for primary, secondary, and tertiary prevention of Chagas' disease

Rassi A., Dias J.C.P., Marin-Neto J.a. Heart (2009) C2

A century after its discovery, Chagas' disease still represents a major public health challenge in Latin America. Moreover, because of growing population movements, an increasing number of cases of imported Chagas' disease have now been detected in non-endemic areas, such as North America and some E... more

Download (122)

View PDF (133)

Point-of-care tests for sexually transmitted infections: target product profiles

World Health Organisation (WHO) (2023) C_WHO

Despite the development of point-of-care diagnostic tests for syphilis, chlamydia, gonorrhoea, and trichomoniasis, none comply with all WHO criteria. This analysis overviews landscape analyses of point-of-care diagnostic technologies for Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vagi... more

Download (171)

View PDF (160)

How to support survivors of gender-based violence when a GBV actor is not available in your area

Inter-Agency Standing Committee (2023) CC

KEY MESSAGES Always talk to a GBV specialist first to understand what GBV services are available in your area. Some services may take the form of hotlines, a mobile app or other remote support. Be aware of any other available services in your area. Identify services provided by humanitarian pa...rtners such as health, psychosocial support, shelter and non-food items. Consider services provided by communities such as mosques/ churches, women’s groups and Disability Service Organizations. Remember your role. Provide a listening ear, free of judgment. Provide accurate, up-to-date information on available services. Let the survivor make their own choices. Know what you can and cannot manage. Even without a GBV actor in your area, there may be other partners, such as a child protection or mental health specialist, who can support survivors that require additional attention and support. Ask the survivor for permission before connecting them to anyone else. Do not force the survivor if s/he says no. Do not proactively identify or seek out GBV survivors. Be available in case someone asks for support. Remember your mandate. All humanitarian practitioners are mandated to provide non-judgmental and non-discriminatory support to people in need regardless of: gender, sexual orientation, gender identity, marital status, disability status, age, ethnicity/tribe/race/religion, who perpetrated/committed violence, and the situation in which violence was committed. Use a survivor-centered approach by practicing: Respect: all actions you take are guided by respect for the survivor’s choices, wishes, rights and dignity. Safety: the safety of the survivor is the number one priority. Confidentiality: people have the right to choose to whom they will or will not tell their story. Maintaining confidentiality means not sharing any information to anyone. Non-discrimination: providing equal and fair treatment to anyone in need of support. If health services exist, always provide information on what is available. Share what you know, and most importantly explain what you do not. Let the survivor decide if s/he wants to access them. Receiving quality medical care within 72 hours can prevent transmission of sexually transmitted infections (STIs), and within 120 hours can prevent unwanted pregnancy. Provide the opportunity for people with disabilities to communicate to you without the presence of their caregiver, if wished and does not endanger or create tension in that relationship. If a man or boy is raped it does not mean he is gay or bisexual. Gender-based violence is based on power, not someone’s sexuality. Sexual and gender minorities are often at increased risk of harm and violence due to their sexual orientation and/or gender identity. Actively listen and seek to support all survivors. Anyone can commit an act of gender-based violence including a spouse, intimate partner, family member, caregiver, in-law, stranger, parent or someone who is exchanging money or goods for a sexual act. Anyone can be a survivor of gender-based violence – this includes, but isn’t limited to, people who are married, elderly individuals or people who engage in sex work. Protect the identity and safety of a survivor. Do not write down, take pictures or verbally share any personal/identifying information about a survivor or their experience, including with your supervisor. Put phones and computers away to avoid concern that a survivor’s voice is being recorded. Personal/identifying information includes the survivor’s name, perpetrator(s) name, date of birth, registration number, home address, work address, location where their children go to school, the exact time and place the incident took place etc. Share general, non-identifying information To your team or sector partners in an effort to make your program safer. To your support network when seeking self-care and encouragement. more

Download (131)

View PDF (402)

Management of a cholera epidemic - Practical guide for doctors, nurses, laboratory technicians, medical auxiliaries, water and sanitation specialists and logisticians
recommended

Médecins Sans Frontières MFS (2023) CC

Cholera is a transmissible diarrhoeal infection caused by Vibrio cholerae. Endemic and/or epidemic in over 40 countries (mainly in Africa and Asia), cholera continues to be a major global public health issue. The World Health Organization (WHO) estimates that the number of cases reported worldwid...e represents in reality only 5 to 10% of actual cases. This guide is intended for medical and non-medical staff responding to a cholera outbreak. It attempts to provide concrete answers to the questions and problems faced by staff, based on the recommendations of reference organisations, such as WHO and UNICEF, as well as Médecins Sans Frontières’ experience in the field. It is divided into 8 chapters. Chapter 1, Cholera overview, outlines the epidemiological and clinical features of cholera. Chapter 2, Outbreak investigation, explains the method and stages of a field investigation, from the alert to implementation of initial activities. Chapter 3, Cholera control measures, details measures and tools to prevent and/or control cholera transmission and mortality in populations affected, or at risk of being affected, by an epidemic (curative care, prevention means and health promotion activities). Chapter 4, Strategies for epidemic response, addresses the roll-out strategies of the measures described in Chapter 3 which depend on context (e.g. urban, rural, endemic, non-endemic setting, etc.), resources and particular constraints. Chapter 5, Cholera case management, details the different stages of cholera treatment, from diagnosis through to cure. Chapter 6, Setting up cholera treatment facilities, focuses on the installation of treatment facilities that vary in size and complexity according to operational requirements (treatment centres and units and oral rehydration points). Chapter 7, Organisation of cholera treatment facilities, describes the organisation of these specialized facilities in terms of human resources, supply, water, hygiene and sanitation, etc. Chapter 8, Monitoring and evaluation, presents the key data to be collected and analysed during an epidemic to facilitate a tailored response and evaluate its quality and effectiveness. The guide includes various practical tools in the appendices to facilitate activities (e.g. water quality tests, job descriptions, documents, etc.). Moreover, the toolbox also contains additional tools in editable formats (individual patient file, cholera case register, pictograms). Despite all efforts, it is possible that certain errors may have been overlooked in this guide. Please inform the authors of any errors detected. To ensure that this guide continues to evolve while remaining adapted to field realities, please send any comments or suggestions. more

Download (95)

View PDF (98)

Report of the fifth WHO stakeholders meeting on gambiense and rhodesiense human African trypanosomiasis elimination

World Health Organization WHO (2023) C_WHO

WHO convened the fifth stakeholders meeting on the elimination of HAT due to infection with Trypanosoma brucei gambiense (g-HAT) and Trypanosoma brucei rhodesiense (r-HAT) in Geneva, Switzerland, on 7–9 June 2023. The meeting was held again in person after the coronavirus disease (COVID-19) pandem... more

Download (6)

View PDF (5)

Mpox Testing Strategy - November 2024

Africa Center for Disease Control and Prevention (2024) CC

Mpox is an emerging zoonotic disease caused by the mpox virus, a member of the Orthopoxvirus genus closely related to the variola virus that causes smallpox. Mpox was first discovered in 1958 when outbreaks of a pox-like disease occurred in monkeys kept for research. The first human case was recorde...d in 1970 in the Democratic Republic of the Congo (DRC) during a period of intensified effort to eliminate smallpox and since then the infection has been reported in a number of African countries. Mpox can spread in humans through close contact, usually skin-to-skin contact, including sexual contact, with an infected person or animal, as well as with materials contaminated with the virus such as clothing, beddings and towels, and respiratory droplets in prolonged face to face contact. People remain infectious from the onset of symptoms until all the lesions have scabbed and healed. The virus may spread from infected animals through handling infected meat or through bites or scratches. Diagnosis is confirmed by polymerase chain reaction (PCR) testing of material from a lesion for the virus’s DNA. Two separate clades of the mpox virus are currently circulating in Africa: Clade I, which includes subclades Ia and Ib, and Clade II, comprising subclades IIa and IIb. Clade Ia and Clade Ib have been associated with ongoing human-to-human transmission and are presently responsible for outbreaks in the Democratic Republic of the Congo (DRC), while Clade Ib is also contributing to outbreaks in Burundi and other countries. In 2022‒2023 mpox caused a global outbreak in over 110 countries, most of which had no previous history of the disease, primarily driven by human-to-human transmission of clade II through sexual contact. In just over a year, over 90,000 cases and 150 deaths were reported to the WHO. For the second time since 2022, mpox has been declared a global health emergency as the virus spreads rapidly across the African continent. On 13 Aug 2024, Africa CDC declared the ongoing mpox outbreak a Public Health Emergency of Continental Security (PHECS), marking the first such declaration by the agency since its inception in 2017.7 This declaration empowered the Africa CDC to lead and coordinate responses to the mpox outbreak across affected African countries. On August 14, 2024, the WHO declared the resurgence of mpox a Public Health Emergency of International Concern (PHEIC) emphasizing the need for coordinated international response. As of August 2024, Mpox has expanded beyond its traditional endemic regions, with new cases reported in countries including Sweden, Thailand, the Philippines, and Pakistan. Sweden has confirmed its first case of Clade 1 variant, which has been rapidly spreading in Africa, particularly in DRC. The emergence of this new variant raises concerns about its potential for higher lethality and transmission rates outside Africa. more

Management of a cholera epidemic - Practical guide for doctors, nurses, laboratory technicians, medical auxiliaries, water and sanitation specialists and logisticians recommended

Management of a cholera epidemic - Practical guide for doctors, nurses, laboratory technicians, medical auxiliaries, water and sanitation specialists and logisticians
recommended